Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
98.20    -0.80 (-0.81%)
Bid:
98.20
Ask:
99.00
Spread: 0.80 (0.815%)
Market Cap: £597.25m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Proposed changes to expense arrangements

24 Nov 2015 10:40

BACIT LIMITED - Proposed changes to expense arrangements

BACIT LIMITED - Proposed changes to expense arrangements

PR Newswire

London, November 24

BACIT LIMITED(a closed-ended investment company incorporated in Guernseywith registration number 55514)

(the "Company")

24 November 2015

Proposed changes to expense arrangements

The Company announces a proposed change to the basis on which the operating expenses of BACIT (UK) Limited, the Company’s investment manager (the “Investment Manager”), are paid with effect from 1 January 2016. The proposed change is subject to shareholder approval. 

The key features of the Company’s investment policy — that it will invest in underlying funds on a “gross return” basis, that it will invest up to one per cent. per annum of its net asset value in drug development projects and that it will donate one per cent. per annum of its net asset value to charities including the Institute for Cancer Research (“ICR”) — will remain unchanged. Both the ICR and the managers of the underlying funds in which the Company currently invests are supportive of the proposed change. 

To date, neither the Investment Manager nor the BACIT investment management team have received a fee from the Company for their investment management services. Under the proposed arrangements, the personnel costs and operating expenses of the investment management function will be covered by a new fee payable by the Company to the Investment Manager equal to 0.19% per annum of the Company’s net asset value. It is not envisaged that the Investment Manager should make a meaningful profit from the fee. Notwithstanding the proposed changes to the expense arrangements Tom Henderson will continue to provide his services as a director of the Company and as CEO of the Investment Manager free of charge. 

A circular, including a notice of an extraordinary general meeting of the Company to approve the proposed changes to the expense arrangements intended to be held at 9.30 a.m. on 11 December 2015 at the offices of Northern Trust International Fund Administration Services (Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3QL will be sent to shareholders shortly. 

A copy of the circular, when published, be available on the Company's website at http://www.bacitltd.com. The Circular will also be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

Enquiries:

Northern Trust International Fund Administration Services (Guernsey) Limited

Tel: +44 (0) 1481 745368

Date   Source Headline
6th Nov 20237:00 amRNSTransaction in Own Shares
2nd Nov 20231:05 pmRNSAutolus to present clinical data updates at ASH
2nd Nov 202311:30 amRNSAutolus reports Q3 2023 Financial Results
2nd Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 20233:36 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSTransaction in Own Shares
31st Oct 20237:00 amRNSTransaction in Own Shares
30th Oct 20237:00 amRNSTransaction in Own Shares
27th Oct 20237:00 amRNSTransaction in Own Shares
26th Oct 202312:00 pmRNSNotice of Results
26th Oct 20237:00 amRNSTransaction in Own Shares
25th Oct 20237:00 amRNSTransaction in Own Shares
24th Oct 20237:00 amRNSTransaction in Own Shares
23rd Oct 20237:00 amRNSTransaction in Own Shares
20th Oct 20237:00 amRNSTransaction in Own Shares
19th Oct 20237:00 amRNSTransaction in Own Shares
18th Oct 202311:00 amRNSProposal to acquire Freeline Therapeutics
18th Oct 20237:00 amRNSTransaction in Own Shares
17th Oct 20237:00 amRNSTransaction in Own Shares
16th Oct 20237:00 amRNSAnaveon to present clinical data update
16th Oct 20237:00 amRNSTransaction in Own Shares
12th Oct 20237:00 amRNSTransaction in Own Shares
11th Oct 20237:00 amRNSTransaction in Own Shares
10th Oct 20237:00 amRNSTransaction in Own Shares
9th Oct 20237:00 amRNSTransaction in Own Shares
6th Oct 20237:00 amRNSTransaction in Own Shares
4th Oct 202312:05 pmRNSSwanBio Provides Clinical and Financing Update
4th Oct 202312:05 pmRNSFreeline Announces Positive Initial Clinical Data
2nd Oct 20231:20 pmRNSTotal Voting Rights
2nd Oct 20237:00 amRNSTransaction in Own Shares
29th Sep 20237:05 amRNSShare Buyback Programme
29th Sep 20237:00 amRNSLaunch of share buyback programme
11th Sep 20237:00 amRNSUpdate on Gyroscope
15th Aug 202312:05 pmRNSFreeline reports Q2 2023 Financial Results
10th Aug 20237:00 amRNSFirst Quarter Update
4th Aug 202312:05 pmRNSPortfolio Update
3rd Aug 202312:05 pmRNSPortfolio Update
1st Aug 20233:08 pmRNSResult of AGM
31st Jul 20231:56 pmRNSTotal Voting Rights
13th Jul 20233:25 pmRNSIssue of shares pursuant to incentive scheme
28th Jun 20237:00 amRNSPublication of 2023 Annual Report & Notice of AGM
15th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSSyncona launches new gene therapy company Beacon
9th Jun 20237:00 amRNSQuell signs collaboration with AstraZeneca
7th Jun 20239:34 amRNSChange of Registered Office - Replacement
7th Jun 20237:00 amRNSChange of Registered Office
2nd Jun 202312:05 pmRNSAutolus presents FELIX data at ASCO
30th May 202312:44 pmRNSFreeline reports Q1 2023 Financial Results
19th May 202311:00 amRNSNotice of Results
15th May 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.